Rivastigmine and Parkinson dementia complex

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 6, 2007, Pages 817-829

  Moretti, Rita ^a   Torre, Paola ^a   Vilotti, Cristina ^a   Antonello, Rodolfo M ^a   Pizzolato, Gilberto ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Acetylcholine; Dementia; Parkinson's disease; Parkinson's disease dementia; Rivastigmine

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANTACID AGENT; ANTIDIABETIC AGENT; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIAZEPAM; DIGOXIN; DONEPEZIL; FLUOXETINE; GALANTAMINE; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PHYSOSTIGMINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TACRINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN; CARBAMIC ACID DERIVATIVE;

ALZHEIMER DISEASE; AMNESIA; BRAIN FUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME INHIBITION; EXTRAPYRAMIDAL SYMPTOM; FOOD; FOOD DRUG INTERACTION; GAIT DISORDER; HALLUCINATION; HEART RATE VARIABILITY; HOSPITAL ADMISSION; HUMAN; LIVER TOXICITY; MEMORY DISORDER; MORTALITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MUSCLE STIFFNESS; NAUSEA; NONHUMAN; NURSING HOME; PARKINSON DISEASE; PATHOGENESIS; PSYCHOSIS; QUALITY OF LIFE; RESTLESSNESS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREMOR; VISUAL HALLUCINATION; VOMITING; ARTICLE; DRUG EFFECT; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

CHOLINESTERASE INHIBITORS; DEMENTIA; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE; PHENYLCARBAMATES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 34247849463     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.6.817     Document Type: Review

References (87)

1. FOLTYNIE T, BRAYNE CEG, ROBBINS TW, BARKER RA: The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2004) 127:1-11.
2. LEVY G, SCHUPF N, TANG MX et al.: Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann. Neurol. (2002) 51:722-729.
3. AARSLAND D, ANDERSEN K, LARSEN JP, LOLK A, NIELSEN H, KRAGH-SORENSEN P: Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology (2001) 56:730-736.
4. AARSLAND D, ANDERSEN K, LARSEN JP, LOLK A, KRAGH-SORENSEN P: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol (2003) 60:387-392.
5. HOBSON P, MEARA J: Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov. Disord. (2004) 19:1043-1049.
6. BRAAK H, RUB U, JANSEN STEUR EN, DEL TREDICI K, DE VOS RA: Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology (2005) 64:1404-1410.
7. KRAYBILL ML, LARSON EB, TSUANG DW et al.: Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology (2005) 64:2069-2073.
8. BOHNEN NI, KAUFER DI, IVANCO LS et al.: Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. (2003) 60:1745-1748.
9. EMRE M: Dementia associated with Parkinson's disease. Lancet Neurol. (2003) 2:229-237.
10. BOEVE BF, SILBER MH, PARISI JE et al.: Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology (2003) 61:40-45.
11. PILLON B, BOLLER F, LEVY R AND DUBOIS B: Cognitive deficits and dementia in Parkinson's disease. In: Handbook of Neuropsychology (2 Edn). Boller F and Cappa S (Eds), Elsevier Sciences B.V., Amsterdam (2001):311-371.
12. MOSIMANN UP, MATHER G, WESNES KA, O'BRIEN JT, BURN DJ AND MCKEITH IG: Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology (2004) 63:2091-2096.
13. CRUCIAN GP AND OKUN MS: Visual-spatial ability in Parkinson's disease. Front Biosci. (2003) 8:992-997.
14. AARSLAND D, CUMMINGS JL AND LARSEN JP: Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int. J. Geriatr. Psychiatry (2001) 16:184-191.
15. SCATTON B, JAVOY-AGID F, ROUQUIER L, DUBOIS B AND AGID Y: Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. (1983) 275:321-328.
16. RINNE JO, PORTIN R, RUOTTINEN H et al.: Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F] fluorodopa positron emission tomographic study. Arch. Neurol. (2000) 57:470-475.
17. KULISEVSKY J: Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Brain Res. (2000) 16:365-79.
18. CASH R, DENNIS T, L'HEUREUX R, RAISMAN R, JAVOY-AGID F, SCATTON B: Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology (1987) 37:42-46.
19. WHITEHOUSE PJ, HEDREEN JC, WHITE CL III AND PRICE DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann. Neurol. (1983) 13:243-248.
20. CANDY JM, PERRY RH, PERRY EK et al.: Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J. Neurol Sci. (1983) 59:277-289.
21. DUBOIS B, RUBERG M, JAVOY-AGID F, PLOSKA A, ACID Y: A subcortico-cortical cholinergic ysrem is affected in Parkinson's disease. Brain Res. (1983) 288:213-218.
22. PERRY EK, CURTIS M, DICK DJ et al.: Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry (1985) 48:413-421.
23. PERRY RH, PERRY EK, SMITH CJ et al.: Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases. J. Neural. Transm. Suppl. (1987) 24:131-136.
24. TIRABOSCHI P, HANSEN LA, ALFORD M et al.: Cholinergic dysfunction in diseases with Lewy bodies. Neurology (2000) 54:407-411.
25. BOHNEN NI, KAUFER DI, IVANCO LS et al.: Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol. (2003) 60:1745-1748.
26. RUB U, DEL TREDICI K, SCHULTZ C, et al.: Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol. Aging (2002) 23:245-254.
27. AARSLAND D, BALLARD C. G., HALLIDAY G: Are Parkinson's disease with dementia and dementia with Lewy bodies the sane entity? J. Geriatr. Psychiatry Neurol. (2004) 17:137-145.
28. EMRE M: What causes mental dysfunction in Parkinson's disease? Mov. Disord. (2003) 18(Suppl. 6): S63-S7.
29. LANGE KW, ROBBINS TW, MARSDEN CD, JAMES M, OWEN AM, PAUL GM: L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berlin) (1992) 107:394-404.
30. COOLS R, BARKER RA, SAHAKIAN BJ, ROBBINS TW: Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and cask demands. Cereb. Cortex (2001) 11:1136-1143.
31. THE FRENCH CLOZAPINE PARKINSON STUDY GROUP: Clozapine in drug-induced psychosis in Parkinson's disease. Lancet (1999) 353:2041-2042.
32. THE PARKINSON STUDY GROUP: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. (1999) 340:757-763.
33. ONDO WG, LEVY JK, VUONG KD, HUNTER C, JANKOVIC J: Olanzapine treatment for dopaminergic-induced hallucinations. Mov. Disord. (2002) 17:1031-1035.
34. BREIER A, SUTTON VK, FELDMAN PD et al.: Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol. Psychiatry (2002) 52:438-445.
35. MORGANTE L, EPIFANIO A, SPINA E et al.: Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol. (2004) 27:153-156.
36. ALBUQUERQUE EX, ALKONDON M, PEREIRA EF et al.: Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J. Pharmacal. Exp. Ther. (1997) 280:1117-1136.
37. GIACOBINI E: Selective inhibitors of butyrylcholinesterase: A valid alternative for therapy of Alzheimer's disease? Drugs Aging (2001) 18:891-898.
38. PERRY EK, PERRY RH, BLESSED G, TOMLINSON BE: Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol. Appl. Neurobiol. (1978) 4:273-277.
39. MESULAM M, GUILLOZET A, SHAW P, QUINN B: Widely spread butyrylcholinesteras can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. (2002) 9:88-93.
40. MESULAM MM, GUILLOZET A, SHAW P, LEVEY A, DUYSEN EG, LOCKRIDGE O: Preservation of cholinergic systems in AChE knockouts and the role of BuChE in acetylcholine hydrolysis. Soc. Neurorci. Abstr. (2001) 27:2565.
41. GROSSBERG GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr. Ther. Res. (2003) 64: 4:216-235.
42. NORDBERG A, SVENSSON AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Saf. (1998) 19:465-480.
43. MASSOULIE J, BON S: The molecular forms of cholinesterase and acetylcholine in vertebrates. Annu. Rev. Neurosci. (1982) 37:57-106.
44. POIRIER J: Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int. J. Clin. Pract. Suppl. (2002) 127:6-19.
45. MASSOULIE J, PEZZEMENTI L, BON S et al.: Molecular and cellular biology of cholinesterases. Prog. Neurobiol. (1993) 41:31-91.
46. INGLIS F: The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl. (2002) 127:45-63.
47. SAITO H, TOGASHI H, YOSHIAKA M et al.: Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. (1995) 22:S257-S259.
48. TOGASHI H, MATSUMOTO M, YOSHIOKA M et al.: Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Behav. Lett. (1994) 166:117-20.
49. KIMURA S, SAITO H, MINAMI M et al.: Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology (2000) 153:167-87.
50. TOGASHI H, KIMURA S, MATSUMOTO M et al.: Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke (1996) 27:520-526.
51. SCREMIN OU, LI MG, SCREMIN AM, JENDEN DJ: Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex. Brain Res. Bull. (1997) 42:59-70.
52. GOTTFRIES CG, BLENNOW K, KARLSSON I, WALLIN A: The neurochemistry of vascular dementia. Dementia (1994) 5:163-167.
53. WALLIN A, BLENNOW K, GOTTFRIES CG: Neurochemical abnormalities in vascular dementia. Dementia (1989) 1:120-130.
54. TOHGI H, ABET, KIMURA M et al.: Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer type dementia. J. Neurol Transm. (1996) 103:1211-1220.
55. VASQUEZ J, PURVE MJ: The cholinergic pathway to cerebral blood vessels. I. Morphological studies. Pflügers Arch. (1979) 379:157-163.
56. VANHOUTTE PM: Endothelium and control of vascular function. State of the art. Hypertension (1989) 13:658-667.
57. SAKURADA T, ALUFUZOFF I, WINBLAD B, NORDBERG A: Substance P like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and mulri-infarct dementia. Brain Res. (1990) 521 (1-2):329-332.
58. SZILAGYAK, NEMETH A, MARTINI E, LENDVAI B, VENTER V: Serum and CSF cholinesterase activity in various kind of dementia. Eur. Arch. Psychiatry Neurol. Sci. (1987) 236:309-311.
59. MESULAM MM: The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. (2004) 145:67-78.
60. POLINSKY RJ: Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin. Ther. (1998) 20(4):634-647.
61. ANAND R, GHARABAWI G: Clinical development of Exelon™ (ENA 713): the ADENA programme. J. Drug Dev. Clin. Pract. (1996) 8:9-14.
62. EXELON™: European Summary of Product Characteristics, Novartis Pharma AG, Basel, Switzerland (29 January 1998).
63. GROSSBERG GT: Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr. Ther. Res. (2003) 64(4):216-235.
64. ENZ A, MEIER D, SPIEGEL R: Effects of novel cholinesterase inhibitors based on the mechanism of enzyme inhibition. In: Alzheimer Disease: Therapeutic Strategies. Giacobini E, Becker R (Eds) Birkhauser, Boston (1994):125-130.
65. BLACKARD WG IR, SOOD GK, CROWE DR, FALLON MB: Tacrine. A cause of fatal heparotoxicity? J. Clin. Gastroenterol. (1998) 26:57-59.
66. BARNES CA, MELTZER J, HOUSTON F et al.: Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience (2000) 99:17-23.
67. WEINSTOCK M: Selectivity of cholinesterase inhibition. CNS Drugs (1999) 12:307-323.
68. POIRIER J: Evidence that clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int. J. Clinc. Pract. Suppl. (2002) 127:6-19.
69. ENZ A, AMSTUTZ R, BODDEKE H et al.: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog. Brain Res. (1993) 98:431-438.
70. WILKINSON DG, PASSMORE P, SMITH R et al.: Comparison of the tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: a 12-week multinational study. 53rd Annual Meeting of the American Academy of Neurology. Philadelphia, USA (29 March - 5 April 2001).
71. READING PJ, LUCE AK, MCKEITH IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord. (2001) 16:1171-1174.
72. MCKEITH I, DEL SER T, SPANO F et al.: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. (2000) 356:2031-2036.
73. VAN LAAR T, VRIES J, LEENDERS K: Rivastigmine is effective and safe as anti-psychotic treatment in patients with Parkinson's disease. The 14th International Congress on Parkinson's Disease. Helsinki, Finland (10 - 14 November 2001).
74. WEISER M, ROTMENSCH HH, KORCZYN AD et al.: A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of coadministration of rivastigmine with risperidone in dementia patients with ehavioural disturbances. Int. J. Geriatr. Psychiatry. (2002) 17:343-346.
75. GROSSBERG G, GAPSAR M, TOUCHON S et al.: Rivastigmine in Alzheimer's disease: Efficacy over 2 years compared with historical controls. Int. Psychogeriatr (2001) 13(Suppl.12):237.
76. BOSBOOM JL, STOFFERS D, WOLTERS ECH: Cognitive dysfunction and dementia in Parkinson's disease. J. Neural. Transm. (2004) 111(10-11):1303-1315.
77. GILADI N, SHABTAI H, GUREVICH T, BENBUNAN B, ANCA M, KORCZYN AD: Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol. Scand. (2003) 108(5):368-373.
78. FOGELSON N, KOGAN E, KORCZYN AD, GILADI N, SHABTAI H, NEUFELD MY: Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol. Scand. (2003) 107(4):252-255.
79. EMRE M, AARSLAND D, ALBANESE A, et al.: Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. (2004) 351(24):2509-2518.
80. MAIDMENT I, FOX C, BOUSTANI M: Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst. Rev. (2006) 25(1):CD004747.
81. WESNES KA, MCKEITH I, EDGAR C, EMRE M, LANE R: Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology (2005) 65:1654-1656.
82. AARSLAND D, BRONNICK K, EHRT U et al.: Neuropsychiatric symptoms in patients with PD and dementia: Frequency, profile and associated caregiver stress. J. Neurol. Neurosurg. Psychiatry. (2006) [Epub ahead of print] doi:10.1136/jnnp.2005.083113
83. BURN D, EMRE M, MCKEITH I et al.: Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov. Disord. (2006) 21(11):1899-1907.
84. GUREVICH TY, SHABTAI H, KORCZYN AD, SIMON ES, GILADI N: Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Mov. Disord. (2006) 21(10):1663-1666.
85. POEWE W, WOLTERS E, EMRE M et al.; EXPRESS INVESTIGATORS: Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study: Mov. Disord. (2006) 21(4):456-461.
86. BALLARD C, LANE R, BARONE P, FERRARA R, TEKIN S: Cardiac safety of rivastigmine in Lewy body and Parkinson's disease demential. Int. J. Clin. Pract. (2006) 60(6):639-645.
87. MIYASAKI JM, SHANNON K, VOON V et al.; QUALITY STANDARDS SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY: Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006) 66(7):996-1002.